Key result
SGLT2 inhibitors, GLP-1 RAs, and PPAR agonists may increase adiponectin in chronic coronary syndromes.
Why the study?
To highlight how contemporary cardiovascular therapies alter adiponectin levels and why this is clinically important for reducing low-grade systemic and vascular inflammation in chronic coronary syndromes.
Do contemporary cardiovascular therapies alter adiponectin levels to reduce inflammation in chronic coronary syndromes?
Do contemporary cardiovascular therapies alter adiponectin levels to reduce inflammation in chronic coronary syndromes?
Contemporary cardiovascular therapies, including SGLT2 inhibitors and GLP-1 receptor agonists, may beneficially modulate adiponectin levels to reduce inflammation in chronic coronary syndromes.
May support adiponectin as a therapeutic target in chronic coronary syndromes; leaves open the need for prospective trials before clinical adoption.
Different degrees of chronic metabolic inflammation and adiponectin resistance significantly contribute to the development of cardiovascular diseases and metabolic syndrome. Adiponectin is a unique pleiotropic adipokine with anti-inflammatory, anti-atherogenic, and anti-diabetic effects. In early metabolic dysfunction, adiponectin levels increase as a compensatory response, whereas in advanced coronary disease, hypoadiponectinemia develops due to adiponectin resistance. The aim of this review is to highlight how contemporary cardiovascular therapies alter adiponectin levels and why this is clinically important for reducing low-grade systemic and vascular inflammation in chronic coronary syndromes. Evidence suggests that drug classes such as PPAR agonists, SGLT2 inhibitors, GLP-1 receptor agonists, RAAS blockers, metformin, certain statins, and fibrates may increase adiponectin levels, although effects vary by drug class and disease stage. Although adiponectin represents a promising therapeutic target for the treatment of coronary syndromes, further experimental and pharmacological research is necessary to develop drugs based on its mechanism of action.
No takes yet. Share an insight, caveat, or question.
Stojanović et al. (2026) conducted a review in Chronic coronary syndromes. Contemporary cardiovascular therapies was evaluated on Adiponectin levels. Contemporary cardiovascular therapies such as PPAR agonists, SGLT2 inhibitors, and GLP-1 receptor agonists may increase adiponectin levels, offering a therapeutic target in chronic coronary syndromes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: